Display options
Cite
Sorensen SF, Zhou W, Dolled-Filhart M, et al. PD-L1 Expression and Survival among Patients with Advanced Non-Small Cell Lung Cancer Treated with Chemotherapy. Transl Oncol. 2016;9(1):64-69doi: 10.1016/j.tranon.2016.01.003.
Sorensen, S. F., Zhou, W., Dolled-Filhart, M., Georgsen, J. B., Wang, Z., Emancipator, K., Wu, D., Busch-Sørensen, M., Meldgaard, P., & Hager, H. (2016). PD-L1 Expression and Survival among Patients with Advanced Non-Small Cell Lung Cancer Treated with Chemotherapy. Translational oncology, 9(1), 64-69. https://doi.org/10.1016/j.tranon.2016.01.003
Sorensen, Steffen Filskov, et al. "PD-L1 Expression and Survival among Patients with Advanced Non-Small Cell Lung Cancer Treated with Chemotherapy." Translational oncology vol. 9,1 (2016): 64-69. doi: https://doi.org/10.1016/j.tranon.2016.01.003
Sorensen SF, Zhou W, Dolled-Filhart M, Georgsen JB, Wang Z, Emancipator K, Wu D, Busch-Sørensen M, Meldgaard P, Hager H. PD-L1 Expression and Survival among Patients with Advanced Non-Small Cell Lung Cancer Treated with Chemotherapy. Transl Oncol. 2016 Feb;9(1):64-69. doi: 10.1016/j.tranon.2016.01.003. PMID: 26947883; PMCID: PMC4800057.
Copy Download .nbib Format: NLM
Share it on

Transl Oncol. 2016 Feb;9(1):64-69. doi: 10.1016/j.tranon.2016.01.003.

PD-L1 Expression and Survival among Patients with Advanced Non-Small Cell Lung Cancer Treated with Chemotherapy.

Translational oncology

Steffen Filskov Sorensen, Wei Zhou, Marisa Dolled-Filhart, Jeanette Baehr Georgsen, Zhen Wang, Kenneth Emancipator, Dianna Wu, Michael Busch-Sørensen, Peter Meldgaard, Henrik Hager

Affiliations

  1. Department of Oncology, Aarhus University Hospital, Norrebrogade 44, DK-8000 Aarhus C, Denmark. Electronic address: [email protected].
  2. Merck & Co., Inc., 2000 Galloping Hill Rd, Kenilworth, NJ, USA. Electronic address: [email protected].
  3. Merck & Co., Inc., 2000 Galloping Hill Rd, Kenilworth, NJ, USA. Electronic address: [email protected].
  4. Department of Pathology, Aarhus University Hospital, Norrebrogade 44, DK-8000 Aarhus C, Denmark. Electronic address: [email protected].
  5. MSD China, 20/F Park Place, 1601 Nanjing Road West, Jin'an District, Shanghai 20040, China. Electronic address: [email protected].
  6. Merck & Co., Inc., 2000 Galloping Hill Rd, Kenilworth, NJ, USA. Electronic address: [email protected].
  7. Formerly of Merck & Co., Inc., 2000 Galloping Hill Rd, Kenilworth, NJ, USA. Electronic address: [email protected].
  8. MSD Denmark, Lautrupbjerg 4, 2750 Ballerup, Denmark. Electronic address: [email protected].
  9. Department of Oncology, Aarhus University Hospital, Norrebrogade 44, DK-8000 Aarhus C, Denmark. Electronic address: [email protected].
  10. Department of Pathology, Aarhus University Hospital, Norrebrogade 44, DK-8000 Aarhus C, Denmark. Electronic address: [email protected].

PMID: 26947883 PMCID: PMC4800057 DOI: 10.1016/j.tranon.2016.01.003

Abstract

BACKGROUND: Recent clinical trial results have suggested that programmed cell death ligand 1 (PD-L1) expression measured by immunohistochemistry may predict response to anti-programmed cell death 1 (PD-1) therapy. Results on the association between PD-L1 expression and survival among patients with advanced non-small cell lung cancer (NSCLC) treated with chemotherapy are inconsistent.

MATERIAL AND METHODS: We evaluated the relationship between PD-L1 expression and overall survival (OS) among 204 patients with advanced NSCLC treated at Aarhus University Hospital, Aarhus, Denmark, from 2007 to 2012. PD-L1 expression was measured using a prototype immunohistochemistry assay with the anti-PD-L1 22C3 antibody (Merck). PD-L1 strong positivity and weak positivity were defined to be traceable to the clinical trial version of the assay.

RESULTS: Twenty-five percent of patients had PD-L1 strong-positive tumors, and 50% had PD-L1 weak-positive tumors. No statistically significant association was found between PD-L1 expression and survival; adjusted hazard ratio of 1.34 (95% confidence interval, 0.88-2.03; median OS, 9.0 months) for the PD-L1 strong-positive group and 1.07 (0.74-1.55; median OS, 9.8 months) for the PD-L1 weak-positive group compared with the PD-L1-negative group (median OS, 7.5 months). No association was seen between PD-L1 expression and OS when PD-L1 expression levels were stratified by median or tertiles.

CONCLUSIONS: In concordance with previous studies, we found PD-L1 measured by immunohistochemistry to be frequently expressed in patients with advanced NSCLC. However, PD-L1 expression is not a strong prognostic marker in patients with advanced NSCLC treated with chemotherapy.

Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.

References

  1. J Thorac Oncol. 2015 Mar;10(3):426-30 - PubMed
  2. Breast Cancer Res Treat. 2013 Jun;139(3):667-76 - PubMed
  3. J Natl Cancer Inst. 2007 Jun 6;99(11):847-57 - PubMed
  4. Oncology (Williston Park). 2014 Nov;28 Suppl 3:39-48 - PubMed
  5. Tumori. 2012 Nov;98(6):751-5 - PubMed
  6. Ann Oncol. 2014 Nov;25(11):2178-84 - PubMed
  7. Cancer Res. 2006 Apr 1;66(7):3381-5 - PubMed
  8. Int Immunol. 2015 Jan;27(1):39-46 - PubMed
  9. Immunotherapy. 2014;6(11):1221-35 - PubMed
  10. Ann Oncol. 2014 Dec;25(12):2433-42 - PubMed
  11. Transl Lung Cancer Res. 2015 Apr;4(2):203-8 - PubMed
  12. Expert Opin Emerg Drugs. 2014 Dec;19(4):557-69 - PubMed
  13. Mol Cancer Ther. 2015 Apr;14(4):847-56 - PubMed
  14. Breast Cancer Res Treat. 2014 Jul;146(1):15-24 - PubMed
  15. Med Oncol. 2011 Sep;28(3):682-8 - PubMed
  16. N Engl J Med. 2002 Jan 10;346(2):92-8 - PubMed
  17. Eur J Cancer. 2014 May;50(7):1361-9 - PubMed
  18. Eur J Surg Oncol. 2015 Apr;41(4):450-6 - PubMed
  19. Lancet Oncol. 2009 Oct;10(10):1001-10 - PubMed
  20. Transl Lung Cancer Res. 2015 Feb;4(1):36-54 - PubMed
  21. Medicine (Baltimore). 2015 Feb;94(6):e515 - PubMed
  22. N Engl J Med. 2015 May 21;372(21):2018-28 - PubMed
  23. Lab Invest. 2014 Jan;94(1):107-16 - PubMed
  24. CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29 - PubMed
  25. Onco Targets Ther. 2014 Apr 12;7:567-73 - PubMed
  26. Br J Cancer. 2015 Jan 6;112(1):95-102 - PubMed

Publication Types